Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection

Zeng,Da‑Wu; Liu,Yu‑Rui; Dong,Jing; Zhu,Yue‑Yong; Li,You‑Bing; Chen,Jing; Zheng,Qi; Jiang,Jia‑Ji

doi:10.3892/mmr.2015.3207

Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection

Authors:
- Da‑Wu Zeng
- Yu‑Rui Liu
- Jing Dong
- Yue‑Yong Zhu
- You‑Bing Li
- Jing Chen
- Qi Zheng
- Jia‑Ji Jiang
View Affiliations

Affiliations: Liver Center, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350005, P.R. China
Published online on: January 16, 2015 https://doi.org/10.3892/mmr.2015.3207
Pages: 3465-3472

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association between hepatitis B surface antigen (HBsAg) and hepatitis B 'e' antigen (HBeAg) levels and liver inflammation and fibrosis in patients with chronic hepatitis B (CHB) in the immune clearance (IC) remains elusive. The aim of the present study was to investigate whether HBsAg and HBeAg levels were associated with liver inflammation and fibrosis in CHB patients during the IC phase. Kendall's rank correlation analysis and receiver operating characteristic curves were used to determine the correlation between HBsAg, HBeAg and liver pathological stages. Multivariate analysis by forward logistic regression was used to analyze significant predictors of cirrhosis. A liver pathology‑predicting model (IC model), which used routinely assessed markers in combination with HBsAg and HBeAg levels, was constructed. There were significantly positive correlations between the HBsAg and HBeAg levels (γ=0.317, P<0.001), and between the HBsAg and HBV‑DNA levels (γ=0.489, P<0.001). However, there was no correlation between the HBsAg and alanine aminotransferase levels. HBsAg and HBeAg levels differed significantly at various liver pathological stages and declined progressively in advanced liver pathological stages. Multivariate logistic regression analysis showed that age, HBsAg and HBeAg levels as well as the international normalized ratio (INR) were independent predictors of liver fibrosis during the IC phase. The IC model had a specificity and sensitivity of 88.64 and 78.24%, respectively, a positive predictive value of 48.15% and negative predictive value of 96.79%. In conclusion, HBsAg and HBeAg levels were negatively and indirectly correlated with liver inflammation and fibrosis in CHB patients in the IC phase. The IC model reliably predicted the probability of liver cirrhosis.

View Figures

View References

1	Liang X, Bi S, Yang W, et al: Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine. 27:6550–6557. 2009. View Article : Google Scholar : PubMed/NCBI
2	Lok AS: Chronic hepatitis B. N Engl J Med. 346:1682–1683. 2002. View Article : Google Scholar : PubMed/NCBI
3	Shi YH and Shi CH: Molecular characteristics and stages of chronic hepatitis B virus infection. World J Gastroenterol. 15:3099–3105. 2009. View Article : Google Scholar : PubMed/NCBI
4	Blumberg BS, Alter HJ and Visnich S: A “new” antigen in leukemia sera. JAMA. 191:541–546. 1965. View Article : Google Scholar : PubMed/NCBI
5	Rotman Y, Brown TA and Hoofnagle JH: Evaluation of the patient with hepatitis B. Hepatology. 49:S22–27. 2009. View Article : Google Scholar : PubMed/NCBI
6	Cornberg M, Protzer U, Dollinger MM, et al: The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepat. 15:1–21. 2008. View Article : Google Scholar : PubMed/NCBI
7	Jaroszewicz J, Calle Serrano B, Wursthorn K, et al: Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 52:514–522. 2010. View Article : Google Scholar : PubMed/NCBI
8	Whitehead TP, Thorpe GHG, Carter TJN, Groucutt C and Kricka LJ: Enhanced luminescence procedure for sensitive determination of peroxidase labelled conjugates in immunoassay. Nature. 305:1581983. View Article : Google Scholar
9	Nguyen T, Desmond P and Locarnini S: The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 3:5–15. 2009. View Article : Google Scholar : PubMed/NCBI
10	Dwivedi M, Misra SP, Misra V, et al: Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission. Indian J Gastroenterol. 30:66–71. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ott JJ, Stevens GA and Wiersma ST: The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis. 12:1312012. View Article : Google Scholar : PubMed/NCBI
12	Chen CH, Lee CM, Hung CH, et al: Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J Gastroenterol Hepatol. 26:461–468. 2011. View Article : Google Scholar : PubMed/NCBI
13	Perrillo R, Mimms L, Schechtman K, Robbins D and Campbell C: Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology. 18:1306–1312. 1993. View Article : Google Scholar : PubMed/NCBI
14	Yen YH, Lu SN, Chen CH, et al: Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int. 27:1349–1355. 2007. View Article : Google Scholar : PubMed/NCBI
15	Cadranel JF, Rufat P and Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 32:477–481. 2000. View Article : Google Scholar : PubMed/NCBI
16	Chan HL, Wong VW, Wong GL, et al: A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 52:1232–1241. 2010. View Article : Google Scholar : PubMed/NCBI
17	Gupta E, Kumar A, Choudhary A, Kumar M and Sarin SK: Serum hepatitis B surface antigen levels correlate with high serum HBV DNA levels in patients with chronic hepatitis B: a cross-sectional study. Indian J Med Microbiol. 30:150–154. 2012. View Article : Google Scholar : PubMed/NCBI
18	Seto WK, Wong DK, Fung J, et al: High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One. 7:e430872012. View Article : Google Scholar : PubMed/NCBI
19	Liu SQ, Zhu XJ, Sun XH, Li M and Gao YQ: Characteristic of liver pathology in HBeAg-positive and HBeAg-negative chronic hepatitis B patients with mildly elevated ALT. Zhonghua Gan Zang Bing Za Zhi. 20:348–352. 2012.(In Chinese). PubMed/NCBI
20	Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al: Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. J Hepatol. 58:1089–1095. 2013. View Article : Google Scholar : PubMed/NCBI
21	Liaw YF, Kao JH, Piratvisuth T, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 6:531–561. 2012. View Article : Google Scholar
22	Scheuer PJ, Standish RA and Dhillon AP: Scoring of chronic hepatitis. Clin Liver Dis. 6:335–47. 2002. View Article : Google Scholar : PubMed/NCBI
23	The programme of prevention and cure for viral hepatitis. Parasitology ASoIDa, Medical aCSoHoC, Association, . Zhonghua Ganzangbing Zazhi. 8. pp. 324–329. 2000
24	Kim SM, Sohn JH, Kim TY, et al: Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease. Korean J Hepatol. 15:454–463. 2009.(In Korean). View Article : Google Scholar : PubMed/NCBI
25	Lee IC, Chan CC, Huang YH, et al: Comparative analysis of noninvasive models to predict early liver fibrosis in hepatitis B e Antigen-negative Chronic Hepatitis B. J Clin Gastroenterol. 45:278–285. 2011. View Article : Google Scholar
26	Tong MJ, Hsu L, Hsien C, et al: A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int. 4:516–522. 2010. View Article : Google Scholar : PubMed/NCBI
27	Park SH, Kim CH, Kim DJ, et al: Development and validation of a model to predict advanced fibrosis in chronic hepatitis B virus-infected patients with high viral load and normal or minimally raised ALT. Dig Dis Sci. 56:1828–1834. 2011. View Article : Google Scholar
28	Poynard T, Ngo Y, Marcellin P, et al: Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat. 16:203–213. 2009. View Article : Google Scholar : PubMed/NCBI
29	Stibbe KJ, Verveer C, Francke J, et al: Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol. 46:962–972. 2011. View Article : Google Scholar : PubMed/NCBI
30	Liaw YF, Leung N, Kao JH, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2:263–283. 2008. View Article : Google Scholar
31	European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 50:227–242. 2009. View Article : Google Scholar
32	Tsai SL, Chen PJ, Lai MY, et al: Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest. 89:87–96. 1992. View Article : Google Scholar : PubMed/NCBI
33	Chu CM and Liaw YF: Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology. 92:220–225. 1987.PubMed/NCBI
34	McMahon BJ, Holck P, Bulkow L and Snowball M: Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 135:759–768. 2001. View Article : Google Scholar : PubMed/NCBI
35	Friedman SL: Liver fibrosis - from bench to bedside. J Hepatol. 38:S38–S53. 2003. View Article : Google Scholar
36	Lee WM: Hepatitis B virus infection. N Engl J Med. 337:1733–1745. 1997. View Article : Google Scholar : PubMed/NCBI
37	Imperial JC: Natural history of chronic hepatitis B and C. J Gastroenterol Hepatol. 14:S1–S5. 1999. View Article : Google Scholar : PubMed/NCBI
38	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. 2012.PubMed/NCBI